TrialThe lancet. Gastroenterology & hepatology2016

Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.

George Lau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.